Last reviewed · How we verify
Aimovig (ERENUMAB)
Aimovig works by blocking the calcitonin-gene-related peptide receptor, a protein involved in migraine pain.
Aimovig (Erenumab) is a small molecule modality developed by Amgen Inc. that targets the calcitonin-gene-related peptide receptor to prevent migraine attacks. It was FDA-approved in 2018 for the prevention of migraine attacks and is currently owned by Amgen Inc. Aimovig is a patented medication with no generic manufacturers available. Key safety considerations include potential allergic reactions and increased risk of infections.
At a glance
| Generic name | ERENUMAB |
|---|---|
| Sponsor | Amgen |
| Target | Calcitonin-gene-related peptide receptor |
| Modality | Monoclonal antibody |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2018 |
| Annual revenue | 500 |
Mechanism of action
Erenumab-aooe is human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function.
Approved indications
- Migraine
- Prevention of migraine attacks
Common side effects
- Injection site reactions
- Constipation
- Injection site pain
- Injection site erythema
- Injection site pruritus
- Cramps
- Muscle spasms
- Hypersensitivity reactions
- Rash
- Angioedema
- Anaphylaxis
- Oral mucosal ulceration
Key clinical trials
- Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action (PHASE4)
- Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45 (PHASE4)
- Fremanezumab, Migraine and Sleep (PHASE4)
- Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine (PHASE3)
- China HeadAche DIsorders RegiStry
- Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease (EARLY_PHASE1)
- Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine (PHASE3)
- A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aimovig CI brief — competitive landscape report
- Aimovig updates RSS · CI watch RSS
- Amgen portfolio CI